Sanjay Chanda's most recent trade in AN2 Therapeutics Inc was a trade of 66,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2026 | 66,000 | 66,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Mar 2026 | 66,000 | 0 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2026 | 57,950 | 57,950 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Mar 2026 | 57,950 | 0 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Mar 2026 | 41,665 | 0 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2026 | 41,665 | 41,665 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2026 | 77,000 | 77,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2026 | 38,000 | 118,823 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 05 Jan 2026 | 5,956 | 75,823 | - | 1.0 | 6,027 | Common Stock |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.00 per share. | 05 Jan 2026 | 3,295 | 81,779 | - | 1.0 | 3,305 | Common Stock |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 100,500 | 100,500 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 50,250 | 80,074 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.34 per share. | 03 Jan 2025 | 2,957 | 29,824 | - | 1.3 | 3,965 | Common Stock |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 27,500 | 28,235 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 27,500 | 28,235 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 57,950 | 57,950 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Sanjay Chanda | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 66,000 | 66,000 | - | - | Stock Option (right to buy) |